OTC : AGYTF

Allergy Therapeutics plc

$0.15 USD

$0 (0.0%)

Volume
7.14K
Average Volume
615
Market Capitalization
$756.3M
P/E Ratio
-6.57
Dividend Yield
0.00%
Price Target
Year High
$0.15
Year Low
$0.09
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.13
Company Overview

OTC

Manuel Llobet

Drug Manufacturers - Specialty & Generic

Healthcare

AGYTF

612

GB

USD

https://www.allergytherapeutics.com

44 1903 844 700

N/A

N/A

Liquidity Metrics

6.30

1.13

0.70

0.31

0.00

Sales & Valuation

$75.56M

5.72

79.93

-8.78

-0.01

Profitability

-$0.0084

-$55.09M

-85.46%

-84.50%

409.00%

-68.96%

P/E Metrics

-6.57

0.46

0.46

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

-0.66

2/9

$4.22M

$71M

$66.76M

-$70.66M

Key Metrics (TTM)

$344.4M

6.01

-10.52

1.13

409.00%

-84.29%

-14.42%

-11.40%

68 days

Company Executives
Name Title
Simon Piggott Head of Clinical Science
Helge Weiner-Trapness Chief Strategy Officer & Director
Sue Baker Head of Human Resources
Matthew Heath Principal Scientist
Alan Bullimore Head of Communication & Market Development
Murray Skinner Chief Scientific Officer
Shaun Antony Furlong Chief Financial Officer & Executive Director
Russell Picket Group Financial Controller
Manuel Llobet Chief Executive Officer & Executive Director
Karley Charlotte Mouatt Cheesman Company Secretary
Poll Results

No votes yet today — be the first to share your view!

About Allergy Therapeutics plc (OTC:AGYTF) Stock

Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes prescription medications specifically designed to address pollen-related allergies, such as those caused by grasses, weeds, and trees, along with various diagnostic tools. Key products in their portfolio feature names like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Pollinex, VLP Peanut, and Penicillin diagnostics. Furthermore, Allergy Therapeutics is actively developing new allergy vaccines targeting a range of allergens, ... including trees, grass, house dust mites, animal dander, and peanuts. The company operates extensively across Central Europe, Southern Europe, the United Kingdom, and extends its market presence internationally. Established in 2004, Allergy Therapeutics plc is based in Worthing, United Kingdom.

FTSE 100 Live: London stocks surge, Wall St volatile as SpaceX trading nears

2026-06-12 12:18:00

FTSE 100 jumps 162 points to 10,466 Brent crude futures fall then rise UK economy contracts 0.1% in April  Housebuilders show strong recovery   4.17pm:...

Allergy Therapeutics to showcase pollen and food allergy progress

2026-06-12 04:15:52

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) said it will use Europe's flagship allergy and clinical immunology congress to showcase progress across its pollen and food allergy pipeline, including clinical proof-of-concept data for its VLP Peanut candidate. The AIM-listed biotechnology company will present 15 posters and oral presentations at the European Academy of Allergy and Clinical Immunology Congress 2026, which takes place in Istanbul, Türkiye, from 12 to 15 June.

Allergy Therapeutics to showcase pollen and food allergy progress

2026-06-12 04:04:00

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) said it will use Europe’s flagship allergy and clinical immunology congress to showcase progress...

Frequently Asked Questions

What is the current Allergy Therapeutics plc (AGYTF) stock price?

Allergy Therapeutics plc(OTC:AGYTF) stock price is $0.15 in the last trading session. During the trading session, AGYTF stock reached the peak price of $0.15 while $0.085 was the lowest point it dropped to. The percentage change in AGYTF stock occurred in the recent session was 0.0% while the dollar amount for the price change in AGYTF stock was $0.

AGYTF's industry and sector of operation?

The OTC listed AGYTF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of AGYTF?

Simon Piggott | Head of Clinical Science
Helge Weiner-Trapness | Chief Strategy Officer & Director
Sue Baker | Head of Human Resources
Matthew Heath | Principal Scientist
Alan Bullimore | Head of Communication & Market Development

How many employees does AGYTF have?

Number of AGYTF employees currently stands at 612. AGYTF operates from Dominion Way, Worthing, WSX BN14 8SA, GB.

Link for AGYTF official website?

Official Website of AGYTF is: https://www.allergytherapeutics.com

How do I contact AGYTF?

AGYTF could be contacted at phone #44 1903 844 700 and can also be accessed through its website. AGYTF operates from Dominion Way, Worthing, WSX BN14 8SA, GB.

How many shares of AGYTF are traded daily?

The average number of AGYTF shares traded daily for last 3 months was 615.

What is the market cap of AGYTF currently?

The market value of AGYTF currently stands at $756.3M with its latest stock price at $0.15